Skip to main content
. 2020 Feb 15;21(4):1312. doi: 10.3390/ijms21041312

Figure 3.

Figure 3

Specificity of [125I]I-PIB-(HE)3-ZHER3:08698-DOTAGA and [111In]In-(HE)3-ZHER3:08698-DOTAGA tumor targeting in Balb/c nu/nu mice bearing BxPC-3 xenografts. The uptake of both imaging probes in tumors was significantly (* p < 0.0001) decreased when a large excess of non-labeled HER3 affibody molecule was administered. Data are presented as average ± SD for four mice.